Pharmaceuticals

Global Idefirix Market Forecast 2026–2035: Long-Term Growth Insights

March 5, 2026March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the idefirix market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Idefirix Market covering 2026–2035?

The historical expansion can be attributed to the scarcity of organs available for kidney transplantation, the extensive presence of donor-specific antibodies, the limitations inherent in conventional desensitization techniques, the initial positive clinical outcomes achieved by imlifidase, and the increasing number of transplant centers.

The anticipated expansion over the projection period stems from heightened demand for kidney transplants, longer transplant waiting lists, greater uptake of precision immunology, enabling regulatory frameworks, and more specialized transplant clinics.

Key developments expected during the forecast timeframe encompass the increased application of desensitization treatments in transplantation, an intensified emphasis on patients with high sensitization, the broader deployment of enzyme-based immunomodulation, a rise in kidney transplant procedures, and better availability of sophisticated transplant care.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20093&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Idefirix Market?

The idefirix market is projected to expand, primarily propelled by the growing prevalence and incidence of kidney diseases. Kidney diseases are health conditions that compromise the kidneys’ structure or function, hindering their vital role in filtering waste and maintaining fluid equilibrium within the body. This rise in kidney disease cases can be attributed to various factors, including an aging population, increasing rates of diabetes and hypertension, certain lifestyle choices, and genetic predispositions. Idefirix, an innovative immunoglobulin G (IgG)-degrading enzyme therapy, provides crucial support to kidney disease patients by allowing highly sensitized individuals to receive life-saving kidney transplants through the effective reduction of donor-specific antibodies, which typically cause transplant rejection. For instance, according to a report published in June 2023 by Kidney Research, a UK-based research organization, the incidence of acute kidney injury is anticipated to increase from an estimated 615,000 cases in 2022 to 637,000 by 2033. Consequently, the increasing prevalence and incidence of kidney diseases are driving the growth of the idefirix market.

What Leading Segments Are Studied In The Idefirix Market?

The idefirix market covered in this report is segmented –

1) By Patient Demographics: Pediatric Patients, Adult Patients

2) By Application: Kidney Transplantation, Desensitization Protocols

3) By End-User: Hospitals, Specialized Clinics, Home Healthcare

4) By Distribution Channel: Direct Sales, Pharmacies

Which Trends Are Expected To Influence The Idefirix Market In The Upcoming Years?

A prominent trend in the idefirix market focuses on developing innovative solutions, such as desensitization treatment, to manage highly sensitized kidney transplant patients. Desensitization treatment is a medical process designed to eliminate or decrease harmful antibodies, thereby enabling transplant recipients to receive organs from incompatible donors. For instance, in July 2023, Hansa Biopharma, a Sweden-based biopharmaceutical company, announced the Australian Therapeutic Goods Administration (TGA), an Australia-based regulatory authority, had approved Idefirix (imlifidase) for use as a desensitization treatment for highly sensitized kidney transplant patients. This approval allows these patients to receive kidney transplants from both living and deceased donors. The treatment operates by reducing or removing harmful anti-donor antibodies, which could otherwise prevent successful transplantation. Based on positive findings from Hansa Biopharma’s phase 2 studies, this approval signifies a major step forward in enhancing kidney transplant options for highly sensitized patients in Australia.

Which Key Market Players Are Investing In Expansion And Innovation Within The Idefirix Market?

Major companies operating in the idefirix market are Hansa Biopharma AB

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/idefirix-global-market-report

Which Regions Are Poised For Strategic Growth In The Idefirix Market?

Europe was the largest region in the idefirix market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the idefirix market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Idefirix Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20093&type=smp

Browse Through More Reports Similar to the Global Idefirix Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Financial Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795